Mereo BioPharma Group plc (MREO)
Nasdaq: MREO · Pharmaceutical Preparations · London · filing with the SEC since 2017
Who runs Mereo BioPharma Group plc
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Scots-Knight Denise
Chief Executive Officer. First filing Jan 2024, latest Feb 2, 2026, 2 filings in all.
Officers reporting now
5
of 13 people with a filing in the last fifteen months
Directors reporting now
8
14 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Scots-Knight Denise | Chief Executive Officer | Jan 2024 | Feb 2, 2026 | none |
| Fox Christine Ann | Chief Financial Officer | Jan 2024 | Feb 2, 2026 | none |
| Hughes-Wilson Alexandra | Chief Patient Access and Commercial Planning | Jan 2024 | Feb 2, 2026 | none |
| Lewicki John A. | Chief Scientific Officer | Jan 2024 | Feb 2, 2026 | none |
| Sermon Charles | General Counsel | Jan 2024 | Feb 2, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bender Jeremy | director | Jan 2024 | Feb 27, 2026 | none |
| Ekblom Anders | director | Jan 2024 | Feb 27, 2026 | none |
| Jacquet Pierre | director | Jan 2024 | Feb 27, 2026 | none |
| Jenkins Annalisa | director | Jan 2024 | Feb 27, 2026 | none |
| Pakianathan Deepika | director | Jan 2024 | Feb 27, 2026 | none |
| Shames Daniel | director | Jan 2024 | Feb 27, 2026 | none |
| Wyzga Michael S | director | Jan 2024 | Feb 27, 2026 | none |
| Yoskowitz Marc J | director | Jan 2024 | Feb 27, 2026 | none |
Earlier names on the record3, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.